The Gene Panel Market: Size, Growth & Who Already Competes

The global gene panel market was valued at roughly $3.68 billion in 2025, and is projected to reach $17.18 billion by 2035 — a 16.69% compound annual growth rate across that decade, according to SNS Insider. Other research houses land on lower but still double-digit growth: Market.us models 14.7% CAGR through 2032. The spread between estimates reflects how differently firms draw the category boundary — some count only hereditary-cancer panels, others include pharmacogenomic and carrier-screening panels in the total. Either way, this is a market growing meaningfully faster than the broader $71.09 billion genetic testing category tracked by Precedence Research, which itself is forecast to reach that figure by 2035.

The growth driver isn't mysterious: panels are replacing single-gene testing as the default order for hereditary cancer, cardiac, and immunodeficiency workups, because sequencing costs have fallen enough that testing 20-80 genes at once costs barely more than testing one.

The five panel categories your positioning should pick from

"Gene panel" is not one product — it's a family of clinical categories, and your plan should say which one (or two) you're actually building around rather than describing the market in the abstract:

• Hereditary cancer panels (20-90 genes) — the largest revenue category, typically billed under CPT 81432 or 81435 depending on scope; BRCA1/BRCA2, Lynch syndrome genes, and CHEK2 are the highest-volume orders
• Cardiac panels (30-170 genes) — cardiomyopathy and arrhythmia gene sets ordered by cardiology and electrophysiology practices, often with a longer sales cycle because ordering volumes per practice are lower
• Pharmacogenomic (PGx) panels (5-30 genes) — genes governing drug metabolism (CYP2D6, CYP2C19 and similar), increasingly ordered pre-emptively by fertility clinics, psychiatry practices, and pain-management groups before prescribing
• Carrier-screening panels (100-500+ genes) — ordered pre-conception or in early pregnancy, usually through OB/GYN and fertility-clinic channels, with a younger, self-pay-tolerant patient population
• Immunodeficiency and epilepsy panels (100-400+ genes) — smaller-volume, pediatric-heavy niches where a boutique lab with strong clinical liaison relationships can out-compete a generalist reference lab

Most first-time lab founders try to launch with all five categories on day one. It's a credibility problem in a plan — accreditation, validation, and proficiency testing have to be completed per panel category, which means each additional category you add at launch pushes your accreditation timeline out and thins your working-capital runway. The stronger plans pick one category, prove the unit economics, and expand the menu in year two once cash flow supports it.

A meaningful share of that market is gated by a small number of national payers. Most commercial insurers and Medicare Advantage plans require prior authorization before a high-cost panel is covered, and each payer maintains its own medical-necessity policy defining which clinical indications qualify. A plan that treats payer coverage as binary — covered or not — misses the operational reality: getting a test authorized, billed, and paid usually takes a dedicated prior-authorization workflow, and the labs that budget staff time for that workflow from day one collect meaningfully more of what they bill than labs that treat it as an afterthought.

Who a new entrant is actually competing against

Before writing a single word of your business plan's market section, it helps to be honest about the competitive set. This is not a fragmented, mom-and-pop niche — it's dominated by a handful of scaled reference labs with deep payer contracts and national sales forces:

• Labcorp — VistaSeq, a portfolio of multi-gene hereditary-cancer panels sold through its Women's Health division
• Ambry Genetics — CancerNext and CancerNext-Expanded, guideline-based and comprehensive hereditary cancer panels
• Quest Diagnostics — a 32-gene guideline-based panel and a 66-gene comprehensive panel covering breast, colon, ovarian and other hereditary cancers
• Invitae — broad hereditary cancer screening panels sold direct to ordering clinicians
• Natera — Empower, a multi-cancer hereditary panel covering 12+ cancer types
• ARUP Laboratories — a university-affiliated reference lab offering both panels and single-gene tests
• Tempus — germline hereditary panels integrated with its broader oncology genomic-profiling platform

None of this means a new lab can't win. It means the plan needs to say explicitly where you beat them — usually turnaround time, a narrower and better-supported clinical niche (a specific cancer type, a specific ancestry population under-served by national panels, or a specific specialty like fertility-clinic pharmacogenomics), or a service layer — dedicated genetic counseling access, faster prior-authorization support — that a high-volume reference lab doesn't prioritize. Investors and lenders read straight through a plan that claims to compete with Labcorp on price; they respond to a plan that names the wedge.

In practice, the wedges that hold up under diligence tend to fall into three patterns. The first is clinical specialization — a lab built around one cancer type or one ancestry population that national panels under-serve, where deep clinical liaison relationships with a handful of specialist referring practices matter more than broad brand recognition. The second is turnaround as a product feature — a committed 7-10 day turnaround backed by a genuinely leaner sample-to-report workflow, marketed directly to time-sensitive referral sources like fertility clinics ahead of an IVF cycle. The third is service bundling — pairing the panel with integrated genetic counseling and payer pre-authorization support so the ordering clinician's office does none of the administrative work, which is often what actually wins a referral relationship away from an incumbent lab.

Questions Clinicians and Patients Actually Ask

These are the questions that come up most often around gene panel testing — worth addressing directly in your plan's market or product section, since they signal what buyers (referring clinicians) and end patients need reassurance on before they'll order or accept a test.

What's the difference between a panel, a single-gene test, and whole-genome sequencing?

A panel tests a curated set of genes tied to one clinical question. Single-gene testing checks one specific gene, usually because a family already has a known mutation. Whole-genome or whole-exome sequencing reads far more of the genome, which means more data but also more variants of uncertain significance (VUS) to interpret and a higher cost per report. Panels are the commercial sweet spot: broad enough to catch what a clinician might not have suspected, narrow enough to keep turnaround and interpretation cost under control.

Can a person be a carrier without any family history?

Yes — most carriers of a genetic condition have no known family history of it, which is a big part of why panel testing has grown faster than testing that's triggered purely by family history. This matters commercially too: it widens your addressable ordering population beyond patients with an obvious red flag.

How fast can a new lab realistically turn results around?

Established labs typically quote two to four weeks. A new entrant's most credible differentiator against Labcorp or Quest scale is often turnaround, not price — a well-run boutique lab processing a narrower panel menu can frequently beat national reference-lab queues, and your business plan's operations section should state a specific, defensible turnaround target rather than a vague "fast service" claim.

What's the difference between a germline and a somatic panel?

A germline panel looks at the DNA a patient was born with — the inherited variants that raise or lower lifetime risk, and the category most hereditary-cancer and carrier-screening panels fall into. A somatic panel instead sequences tumor tissue to find mutations that arose after birth, used to guide which cancer therapy is likely to work. The two require different validation, different consent processes, and often different CPT codes — a plan that conflates them in its clinical-scope section is an immediate red flag to a genetics- literate reviewer, whether that's a lender's diligence team or a referring oncologist deciding whether to trust your lab.

Should genetic counseling be billed separately, or bundled into the test price?

Newer CPT codes increasingly allow genetic counseling to be billed as its own line item rather than folded into the test charge, which matters for your revenue model: a lab that treats counseling purely as a cost center is leaving a recurring, relationship-building revenue stream on the table. Most established panel providers now separate the two on the invoice, both because it reflects the actual clinical work involved and because it keeps the per-test reimbursement figure cleaner for payer negotiation purposes.

Startup Costs & Funding Routes

Building a CLIA/CAP-track gene panel lab in the US typically requires $150,000 to $850,000; the equivalent UKAS ISO 15189-track lab in the UK runs £120,000 to £650,000. The single biggest swing factor is whether you sequence in-house from day one or outsource sequencing to a contract lab while you build volume — outsourcing can cut your year-one capital need by $150,000-$250,000 at the cost of thinner per-test margin.

Cost Breakdown

• CLIA/CAP-compliant lab build-out (biosafety cabinets, pre-/post-PCR separation, cold-chain storage): $45,000–$220,000 (£35K–£175K)
• NGS sequencing capability — outsourced in year one, or an in-house benchtop instrument such as an Illumina MiSeq or NextSeq 2000: $0–$250,000 (£0–£200K)
• Library prep reagents, extraction kits & consumables (first 12 months): $30,000–$120,000 (£24K–£95K)
• Bioinformatics / variant-interpretation software licensing (platforms in the SOPHiA DDM / Emedgene category): $15,000–$70,000/yr (£12K–£55K/yr)
• CLIA certification, CAP accreditation survey & proficiency testing enrolment: $8,000–$35,000
• Genetic counseling staff (board-certified counselor, first-year salary + benefits): $70,000–$110,000 (£45K–£70K)
• Professional liability + data-privacy insurance (genomic data is high-sensitivity PHI): $6,000–$18,000 (£5K–£15K)
• Working capital — payer reimbursement lag averages 60-120 days, so budget accordingly: $60,000–$200,000 (£48K–£160K)

Funding Routes

In the US, SBA 7(a) loans cover up to $5M with terms up to 25 years and remain the standard debt-financing route for medical laboratory businesses (NAICS 621511), though most SBA lenders will scrutinize the accreditation timeline closely before releasing funds tied to lab build-out. Because CLIA/CAP certification can take four to six months once an inspection is scheduled, structure any loan draw schedule around that gate rather than assuming revenue starts on day one. Equity from healthcare-focused angel networks or seed funds is common for labs planning to build proprietary panel content or a bioinformatics pipeline, since that IP is what makes the business fundable beyond a simple lab-services model.

In the UK, the Start Up Loans scheme offers up to £25,000 at 6% fixed interest with free mentoring — rarely enough alone to fund a lab, but useful as part of a blended raise alongside angel investment or an Innovate UK grant, both of which are common for founders coming out of NHS genomics roles with a specific clinical niche in mind. Our bespoke business plan service builds the financial model to whatever funding mix you're pursuing, formatted for SBA, UK Start Up Loans, or private investor due diligence.

The 12-18 month runway from lease to first billable test

A realistic capital plan has to account for the gap between signing a lease and reporting your first billable result — this is where most first-time founders underfund the business. A typical sequence runs: months 1-3 for lab build-out and equipment installation; months 3-6 for assay validation, standard operating procedure documentation, and proficiency-testing enrolment; months 6-10 for the CLIA/CAP (or UKAS) inspection cycle itself; and months 10-12 for payer credentialing and contracting, which frequently runs in parallel with accreditation but can extend past it. Labs that assume revenue begins the moment the lab is physically built routinely run out of working capital in month eight or nine — the single most common reason a promising gene panel startup fails before it ever bills its first payer.

Where Gene Panel Labs Actually Cluster

Unlike a restaurant or a daycare, a gene panel business is not primarily a local-demand business — it's a lab-services business that benefits enormously from clustering near genomics talent, academic medical centers, and existing biotech infrastructure, even though its customers (referring clinicians and patients) can be anywhere.

• Boston / Cambridge, MA — the densest US genomics and biotech talent pool, home to multiple reference labs and academic sequencing cores; high rent and salary costs but the fastest path to hiring experienced lab directors and bioinformaticians
• Research Triangle, NC (Durham/Raleigh) — lower cost of living than Boston or the Bay Area with strong university-lab talent pipelines from Duke and UNC; increasingly popular for new diagnostics startups
• San Diego, CA — dense genomics and life-sciences cluster with easier access to specialized lab-equipment vendors and contract sequencing providers
• Salt Lake City, UT — home to ARUP Laboratories and a growing diagnostics-industry base with comparatively lower operating costs
• Cambridge / Oxford, UK — the UK's genomics research corridor, close to NHS Genomic Medicine Service Alliance labs and a strong pipeline of clinical genetics talent
• Manchester, UK — home to the North West Genomic Laboratory Hub; a realistic base for a lab wanting proximity to NHS-adjacent genomics infrastructure outside the South East's higher costs

There's also a genuine remote-operating model worth considering in the plan: because samples travel by mail (a buccal swab or blood draw kit rather than something requiring in-person collection), a gene panel lab doesn't strictly need to be near its ordering clinicians the way a daycare or a restaurant needs to be near its customers. Several panel-testing businesses run a centralized lab in a lower-cost secondary market and build referral relationships nationally through clinical liaison staff who travel to conferences and practices rather than relying on local geographic demand — a model worth stating explicitly if it's the one you're pursuing, since it changes how a lender or investor should read your addressable market.

If you're not locating in one of these clusters, your plan should explicitly address how you'll recruit CLIA-qualified genetics personnel (in the US, staff need four years of laboratory training or experience in genetics, at least two of which are in clinical genetics, before they can be listed on your CLIA certificate) — this single staffing requirement is one of the most common reasons first-time lab founders underestimate their timeline to first billable result.

The cost trade-off is real and worth modeling explicitly in your plan. A lab director or senior molecular geneticist in Boston or the Bay Area commonly commands a salary premium of 20-35% over the same role in the Research Triangle or Salt Lake City, and commercial lab space in those coastal hubs can run two to three times the per-square-foot cost of a secondary genomics market. For a lean, outsourced-sequencing launch, that premium rarely pays for itself in year one — it starts to matter more once you're recruiting a full bioinformatics team and need to compete directly for talent against nearby biotech and pharma employers.

Revenue Model, Reimbursement & Margins

The single most important number in a gene panel business plan is not the list price of your test — it's the gap between list price and blended net reimbursement. A comprehensive hereditary cancer panel billed under CPT 81432 carries a list charge above $2,500, but Medicare currently reimburses approximately $1,117.98 for that same code, and commercial payers negotiate their own contracted rates that typically fall somewhere between the two. Most commercial payers and Medicare Advantage plans also require pre-authorization before a high-cost panel will be covered at all, which means a portion of ordered tests will be denied, delayed, or converted to patient self-pay regardless of how good your lab work is.

Worked example

A boutique lab processing 500 hereditary-cancer and pharmacogenomic panels a month at a blended net reimbursement of $650 per test (after contractual write-downs across Medicare, Medicaid and commercial payers) generates roughly $325,000 in monthly revenue, or close to $3.9 million annually. Direct cost per test — extraction, library prep, sequencing run allocation, and variant-interpretation review — typically runs $180 to $340. After genetic-counselor staffing, bioinformatics licensing, accreditation-maintenance costs, and payer-denial write-offs, net margins in this niche commonly settle in the 5–20% band — noticeably tighter than most diagnostics categories because of CPT-code reimbursement pressure and the near-universal requirement for prior authorization on high-cost panels.

Additional revenue levers worth modeling explicitly: reflex confirmatory testing (a positive panel result often triggers a second, separately billable confirmatory test), genetic counseling consultation fees (increasingly billable in their own right under newer CPT codes), and direct institutional contracts with fertility clinics or oncology practices that guarantee volume in exchange for negotiated turnaround-time commitments — a structure that smooths out the payer-mix volatility that hits pure fee-for-service labs hardest.

Year one versus year three, modeled honestly

Payer credentialing and denial rates improve with time, and your forecast should reflect that rather than assuming steady-state margins from day one. In year one, expect a higher proportion of self-pay and out-of-network billing while payer contracts are still being negotiated, denial rates in the 20-25% range as your prior-authorization process is still maturing, and monthly volume ramping slowly as referral relationships build. By year three, a lab with a genuinely differentiated niche typically sees denial rates fall into the 10-15% range, payer mix shift toward in-network contracted rates, and volume scale two to four times its year-one run rate as word-of-mouth among referring clinicians compounds. A plan that shows flat margins across five years reads as unresearched; a plan that shows the specific mechanics of that improvement — contract-by-contract, category- by-category — reads as credible.

What lenders and investors actually scrutinize

Reviewers who have seen more than a handful of diagnostics plans go straight to three numbers: the gap between list price and blended net reimbursement (because it's the number most first-time founders get wrong), the accreditation timeline versus the funding draw schedule (because a mismatch there is the most common cause of a mid-build cash crunch), and the payer-mix assumption (because a plan that assumes an unrealistically favorable mix of in-network, high-reimbursement payers is the fastest way to lose credibility with anyone who has actually run a clinical lab's revenue cycle). Addressing all three explicitly, with cited figures rather than round numbers, is what separates a fundable plan from a template with the blanks filled in.

Accreditation: CLIA, CAP, UKAS & IVDR

United States

• CLIA certification (Certificate of Compliance or Accreditation for high-complexity genetic testing) from CMS — costs $150–$8,000 biennially depending on certificate type and volume; a Certificate of Waiver can take 60-120 days, while Compliance/Accreditation typically takes 120+ days once inspection is scheduled
• CAP Laboratory Accreditation from the College of American Pathologists — a CAP inspection can satisfy CLIA requirements and reduce the frequency of separate CMS inspections, but adds its own several-thousand-dollar annual fee on top of CLIA
• Genetics personnel qualification standard — CLIA requires that testing personnel hold four years of laboratory training or experience in genetics, at least two of which are in clinical genetics, before they can be listed on your certificate; this is the requirement first-time founders most often underestimate
• Two proficiency testing (PT) events per year, mandatory for CLIA-certified labs
• State-level clinical laboratory licensure where applicable (varies by state, in addition to federal CLIA)
• HIPAA compliance for genomic data, which is treated as especially sensitive protected health information

United Kingdom

• UKAS ISO 15189:2022 medical laboratory accreditation, which explicitly covers the genetics discipline — assessment plus annual surveillance fees typically run £10,000–£30,000 depending on scope, with an initial assessment cycle of 6-12 months
• Alignment with the National Genomic Test Directory if pursuing NHS Genomic Medicine Service commissioned volume — the Test Directory is reviewed on an annual evidence-based cycle and sets out which indications each commissioned test can be used for
• MHRA oversight if you develop and validate your own in-house assay (a laboratory-developed test), which is an ongoing compliance obligation rather than a one-time certificate
• Data protection registration under UK GDPR — genomic data is special-category data requiring explicit additional safeguards
• Professional indemnity and public liability insurance appropriate to clinical laboratory operations

European Union

If you plan to sell into EU markets, genetic panel tests generally fall into IVDR (Regulation (EU) 2017/746) Class C, which requires Notified Body conformity assessment rather than manufacturer self-certification. IVDR has been fully applicable since 26 May 2022, and Class C devices need substantially more clinical-evidence documentation than the equivalent test needed under the older IVDD regime — budget for this as a separate, non-trivial compliance workstream if EU distribution is part of your plan rather than a same-day extension of your UK or US accreditation.

Two other jurisdictions come up often enough in gene panel business plans to flag briefly. Canada regulates laboratory-developed genetic tests primarily at the provincial level (through provincial health-laboratory licensure) rather than a single national gate, with Health Canada involved mainly where a kit-based device is being sold rather than a lab-developed test being run in-house. Australia requires NATA (National Association of Testing Authorities) accreditation for clinical genetic testing laboratories, broadly analogous in function to UKAS or CAP. Neither should be treated as a same-day extension of your primary accreditation — each carries its own inspection cycle and its own personnel-qualification standard.

Five Mistakes First-Time Lab Founders Make

1. Opening before accreditation is actually finalized. The CLIA/CAP (or UKAS ISO 15189) inspection queue alone can run four to six months, and you cannot legally report a single patient result before certification lands. Founders who model revenue starting at month three routinely find themselves burning working capital for two extra quarters with zero billable activity.
2. Pricing off list charge instead of blended net reimbursement. A $2,500 sticker price means little when Medicare pays roughly $1,118 and commercial payers each negotiate their own rate. Plans that use list price as the revenue assumption overstate income by 50% or more.
3. Launching without a board-certified genetic counselor on staff or on contract. This creates both a liability gap and a trust gap — referring physicians are increasingly reluctant to order from a lab that can't offer counseling support alongside results, particularly for cancer-risk panels.
4. Trying to compete on price against Labcorp, Quest, or Ambry. Scaled reference labs win on procurement power and existing payer contracts that a new entrant cannot match in year one. A defensible plan competes on turnaround time, a narrower clinical niche, or a service layer — not on undercutting national list pricing.
5. Ignoring variant reclassification obligations. When a variant of uncertain significance (VUS) is later reclassified as pathogenic or benign, labs are generally expected to recontact the ordering clinician. The cost of maintaining that recontact pipeline — software, staff time, and a documented process — is rarely budgeted at launch, and it's exactly the kind of line item that surfaces during investor or lender diligence.
6. Launching a full multi-category panel menu instead of proving one category first. Each additional panel category — hereditary cancer, cardiac, pharmacogenomic, carrier screening — requires its own validation and proficiency testing before it can go live. Founders who list six categories in their launch plan routinely find accreditation stretches from six months to over a year, while a single-category launch can often reach first billable result faster and use early revenue to fund category two.

Sample Business Plan Preview

Here's an extract from a real gene panel business plan written by our team, so you can see exactly what you'll get:

What's in the Template

Every Avvale business plan template includes these sections, pre-structured for your industry:

• Executive Summary — Your business at a glance, written to hook investors and lenders in 60 seconds
• Company Overview — Legal structure, ownership, laboratory location, and founding story
• Industry Analysis — Market size, growth trends, reimbursement environment, and accreditation requirements
• Customer Analysis — Referring-clinician segments, patient population, and ordering behavior
• Competitor Analysis — Reference-lab mapping (Labcorp, Quest, Ambry-scale competitors) and your differentiation strategy
• Marketing Plan — Clinician outreach channels, conference presence, and referral-network development
• Operations Plan — Sample-to-report workflow, staffing structure, turnaround-time targets, and accreditation milestones
• Management Team — Founder bios, lab director credentials, advisory board, and key hires planned

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with income statement, cash flow, balance sheet, break-even analysis by panel volume, and payer-mix sensitivity — the exact structure SBA lenders and healthcare-focused investors expect to see for a lab-services business. If you're planning a broader molecular diagnostics offering rather than a focused panel menu, our molecular diagnostic business plan template covers that wider model, and if direct-to-consumer testing (ancestry, paternity) is part of your roadmap, see our DNA testing business plan template. For general startup guidance beyond the industry specifics, our business plan writer service can take the whole process off your plate.

Frequently Asked Questions